ABSTRACT
@# Cell therapy includes stem cell therapy and immunotherapy for multiple diseases including cancer. With the progress in life science and medicine as well as people’s increasing demands for health, cell therapy has become an important frontier research field. Constantly emerged innovative theories, technologies and clinical outcomes of cell therapy have laid a solid foundation for the development of cell therapy industrialization. Now some cell therapy products have already been approved by the regulatory authorities abroad; and in China, cell therapy is in a period of great opportunities. Therefore, how to optimize the supervision and guiding system and provisions, to better stimulate the vitality of research and transformation, to create more benefits for patients and to promote the development of the industry in an orderly manner have become an issues that worth deep consideration. In this paper, we discussed the current progress on stem cell therapy and immunotherapy represented by chimeric antigen receptor T-Cell (CAR-T) in both domestic and overseas, and the industry supervision of cell therapy in China; in addition, we also put forward some suggestions for the development of cell therapy in China for the reference of peers in this field.
ABSTRACT
Neoantigens, as the products of gene mutations in tumor cells, are specific antigen expressed on the surface of tumor cells. They can be the targets of immuno-cell therapies with high specificity and safety. Immunotherapies based on tumor neoantigens became the new research hotspot as results of the applications of genomic sequencing technologies and the development of neoantigens prediction techniques. In this paper, the applied prospect of neoantigens in hematological malignancies is discussed based on the research progress in the last few years and the relevant reports from the 59th American Society of Hematology Annual Meeting.
ABSTRACT
The growing knowledge of cancer immunology during the past 20 years has led to the current implementation of immunotherapy. Immuno-cell therapy, in which ex vivo processed T lymphocytes and dendritic cells are used as agents, has developed and spread and is now accepted as a common treatment with the identification of a number of cancer peptide antigens. The response rate to immuno-cell therapy is reported to be around 10-20%. Some clinical studies have reported that immuno-cell therapy as a postoperative adjuvant therapy improved survival rates. This paper outlines the historic background and the current medical scene of immuno-cell therapy.<br>